Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Medical Device

Intuitive Surgical’s Ion Robotic System Gains Regulatory Approval in China

Fineline Cube Mar 22, 2024

Intuitive Surgical (NASDAQ: ISRG), a leading medical robotics firm based in the US, has announced...

Company

Henlius Biotech Posts 67.8% YOY Revenue Growth and First Annual Profit in 2023 Financials

Fineline Cube Mar 22, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696) has released its financial results for 2023, reporting revenues...

Company

Bayer Eliminates C-Level Roles in Restructuring Efforts to Boost Profitability

Fineline Cube Mar 22, 2024

Germany’s Bayer (ETR: BAYN) has taken significant steps in its restructuring efforts by eliminating 8...

Company Deals Digital

Baidu Health Partners with Yibang to Enhance Operations for Brick-and-Mortar Pharmacies

Fineline Cube Mar 21, 2024

Baidu Health has entered into a strategic partnership with Shanghai Yibang Medicine Information Technology Co.,...

Company Deals

Edan Instruments Partners with Global Health Labs to Develop AI-Enhanced Handheld Ultrasound

Fineline Cube Mar 21, 2024

Shenzhen-based Edan Instruments Inc. has forged a strategic partnership with Global Health Labs Inc. to...

Company Drug

FDA Grants Accelerated Approval for Takeda’s Iclusig in Newly Diagnosed Ph+ ALL

Fineline Cube Mar 21, 2024

The U.S. Food and Drug Administration (FDA) has granted accelerated indication extension approval to Japan’s...

Policy / Regulatory

China Unveils Action Plan to Boost Foreign Investment and Open Economy Further

Fineline Cube Mar 21, 2024

The State Council of China has unveiled an ambitious “Action Plan to Promote the High-Level...

Company

Simcere Pharmaceutical Reports 4.5% Revenue Growth in 2023 Amid Shifts in Profitability

Fineline Cube Mar 21, 2024

Simcere Pharmaceutical Group (HKG: 2096), based in China, has released its 2023 financial performance report,...

Company Deals

Sinopharm and Fresenius Kabi Expand Partnership to Enhance Drug Distribution and Healthcare Services

Fineline Cube Mar 21, 2024

China’s state-owned Sinopharm Group Co., Ltd. (HKG: 1099) has announced a new partnership with Germany’s...

Company Deals

Bayer and Thermo Fisher Partner to Develop Rapid Companion Diagnostics for Precision Oncology

Fineline Cube Mar 21, 2024

Germany’s Bayer (NYSE: BAYE) has entered into a strategic partnership with U.S. life sciences leader...

Company Drug

iRegene’s NouvSight001 Gains Orphan Drug Designation for Retinitis Pigmentosa Treatment

Fineline Cube Mar 21, 2024

Wuhan-based cell therapy innovator iRegene has secured Orphan Drug Designation (ODD) from the U.S. FDA...

Company Drug

BMS Reports Positive Phase III Results for Opdivo and Yervoy in Advanced HCC

Fineline Cube Mar 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) announced this week that its Phase III study evaluating...

Company Deals

China Resources Guangdong Pharmaceutical Partners with BD to Enhance Drug and Device Distribution in GBA

Fineline Cube Mar 21, 2024

China Resources Guangdong Pharmaceutical Co., Ltd has entered into a strategic partnership with U.S.-based Becton,...

Digital R&D

CAIR Launches CARES Copilot 1.0: A Revolutionary AI Chatbot for Medical Diagnosis and Treatment

Fineline Cube Mar 21, 2024

The Centre for Artificial Intelligence and Robotics (CAIR), part of the Chinese Academy of Sciences...

Company Deals

VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology

Fineline Cube Mar 21, 2024

VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a...

Company Drug

Antengene’s ATG-022 Advances to Dose Expansion Phase in Phase II CLINCH Study for Solid Tumors

Fineline Cube Mar 21, 2024

Antengene Corporation Ltd (HKG: 6996), a leading biopharmaceutical company based in China, has announced that...

Company Drug

CSPC Pharmaceutical Secures NMPA Approval for Clinical Study of SYS6023 in Advanced Solid Tumors

Fineline Cube Mar 21, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent China-based biopharmaceutical company, has received approval from...

Company

3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics

Fineline Cube Mar 21, 2024

3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results,...

Company

Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales

Fineline Cube Mar 21, 2024

Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors

Fineline Cube Mar 20, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Posts pagination

1 … 387 388 389 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.